<DOC>
	<DOCNO>NCT01757418</DOCNO>
	<brief_summary>The purpose study determine whether intravenous immune globulin safe effective acute treatment pain crisis sickle cell disease . Funding Source : Food Drug Administration ( FDA ) , Office Orphan Products Development ( OOPD )</brief_summary>
	<brief_title>Intravenous Gammaglobulin Sickle Cell Pain Crises</brief_title>
	<detailed_description>Patients randomize single dose IVIG versus normal saline placebo uncomplicated pain crisis . Length VOC secondary endpoint monitor .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Documented diagnosis sickle cell disease ( SS Sβ thalassemia genotype ) Age 1265 year Phase 1 , 821 year Phase 2 Uncomplicated acute pain episode require hospital admission parenteral narcotic Increased stroke risk assess transcranial Doppler magnetic resonance imaging ( subject undergo test ) Concomitant acute process , include fever &gt; 38.5° C clinical suspicion infection Increased ALT &gt; 2X ULN Serum creatinine ≥1.3 mg/dL , &gt; 300 mg/dL protein spot urinalysis , know condition associate renal dysfunction Hb &gt; 10 g/dL Hct &gt; 30 % Known IgA deficiency know allergy gamma globulin Pregnancy breastfeed Vaccination live attenuate virus precede 6 week Documented history illicit ( eg . heroin , cocaine ) drug abuse drugseeking behavior Current participation another investigational drug study Current treatment chronic transfusion Prior thrombose current estrogen use</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Pain</keyword>
	<keyword>Immune Globulin</keyword>
</DOC>